Physicians' Academy for Cardiovascular Education

There is hope for treatment of HFpEF

Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore

Highly adhering to a plant-based diet is associated with a lower risk of developing HF

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA

Heart failure & Diabetes: Time for a more unified approach

Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017

Step forward in telemonitoring through use of an algorithm that risk-stratifies HF patients

May 31, 2017 - ESC HF 2017, Paris

Disappointing results with therapy for acute heart failure

Apr. 30, 2017 - ESC HF 2017, Paris

Challenges in Heart Failure management: Diabetes and Renal Impairment

May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

New diabetes drugs and heart failure: What have we learnt?

May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris

New diabetes treatments with CV benefit: A changing role for the cardiologist

Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

HFpEF in older adults: TTR amyloid, under diagnosed and treatable?

Nov. 12, 2016 - New Orleans, LA, USA - Mathew S. Maurer, MD (New York, NY, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Peak VO2 maintained in HF patients on IV iron therapy

Nov. 22, 2016 - AHA 2016 - Dirk Jan van Veldhuisen, MD (UMC Groningen, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

Iron deficiency in the new HF guidelines

Aug. 29, 2016 - Peter van der Meer, MD - University Medical Center Groningen, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Extra work of checking device data weekly does not translate into benefit for HF patient

Oct. 25, 2016 - ESC - 2016 Rome - Martin Cowie, MD - National Heart & Lung Institute, London, UK
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure news at the ESC

Aug. 29, 2016 - ESC - 2016 Rome - Frank Ruschitzka, MD - University Heart Center, Zurich, Switzerland
##SCROLLER_ITEMS_FULL_TITLE##

Heart Failure news from ESC 2016 at a glance

Sep. 21, 2016 - ESC - 2016 Rome - Prof. Mariell Jessup (Philadelphia, PA, USA)

HF & Diabetes: SGLT2 inhibition a paradigm shift?

Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

The future of HF management: How does potassium binding fit within pharmacological treatment of heart failure?

June 28, 2016 - ESC HF 2016, Florence, Italy - Kenneth Dickstein, MD - University of Bergen Stavanger University Hospital, Norway

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

RAAS inhibition in heart failure: Corner stone of therapy & potassium homeostasis

May 23, 2016 - ESC HF 2016, Florence, Italy - Faiez Zannad, MD - CHU- Nancy University Nancy, France

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Current treatment of Diabetes in Heart Failure

May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands

Two additions to the therapeutic armory to treat HFrEF

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Scott D. Solomon, MD - Boston, MA, USA

Managing cardiorenal syndrome in the context of heart failure

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter A. McCullough, MD - Dallas, TX, USA
##SCROLLER_ITEMS_FULL_TITLE##

New 2016 ESC Heart Failure Guidelines

May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors (Groningen, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

The spectrum of Heart Failure

May 11, 2016 - Boston, MA, USA - Dr. Marc Pfeffer
##SCROLLER_ITEMS_FULL_TITLE##

Review of cardiovascular safety of DPP4 inhibitors

May 6, 2016 - Dubai, UAE - Dr Sanjay Rajagopalan, MD, Maryland
##SCROLLER_ITEMS_FULL_TITLE##

No benefit of direct renin inhibition in HF in ATMOSPHERE trial

Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Lars Køber
##SCROLLER_ITEMS_FULL_TITLE##

HF Summit : innovation in clinical care in heart failure

Oct. 31, 2015 - Barcelona, Spain - Prof. Adriaan Voors and Prof. Martin Cowie
##SCROLLER_ITEMS_FULL_TITLE##

A multidisciplinary approach in heart failure management

Oct. 31, 2015 - Barcelona, Spain - Aldo Maggioni, TIny Jaarsma, Richard Hobbs and Josep Comin-Colet

There is hope for treatment of HFpEF

Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore
Professor Lam lists five mechanisms in which she recognizes targets for treatment of patients with heart failure with preserved ejection fraction. These mechanisms are currently tested as therapeutic strategies.

Professor Lam lists five mechanisms in which she recognizes targets for treatment of patients with heart failure with preserved ejection fraction. These mechanisms are currently tested as therapeutic strategies.

Fewer ventricular arrhythmias with angiotensin-neprilysin vs angiotensin inhibition in HF

Dec. 18, 2017 - de Diego C et al. - Heart Rhythm 2017

In HFrEF patients with an ICD under remote control, treatment with ARNI decreased ventricular arrhythmias and appropriate ICD shocks as compared to angiotensin inhibition alone.

New onset and paroxysmal AF increase the risk of adverse outcomes in HF

Dec. 6, 2017 - Mogensen UM et al. - J Am Coll Cardiol. 2017

In heart failure patients with a reduced EF, paroxysmal AF and new onset AF were associated with a greater risk of adverse outcomes, including HF hospitalization and stroke, but not mortality.

HFrEF patients with low SBP do tolerate target dose of ARNI

Nov. 30, 2017 - Senni M, et al. - Eur J Heart Fail 2017

In an analysis of the TITRATION study, the majority of patients with low screening SBP tolerated the initiation/up-titration to target dose level of sacubitril/valsartan using a gradual up-titration regimen.

Highly adhering to a plant-based diet is associated with a lower risk of developing HF

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA
Kyla Lara presented a poster at the AHA on her research on the effect of various dietary patterns, based on Food Frequency Questionnaires, on the risk of developing heart failure.

AHA 2017 Kyla Lara presented a poster at the AHA on her research on the effect of various dietary patterns, based on Food Frequency Questionnaires, on the risk of developing heart failure.

Diabetes and microvascular complications predict outcomes in HFpEF

Oct. 31, 2017 - Sandesara PB et al. - Diabetes Care 2017

In the TOPCAT study, diabetes and its microvascular complications carried important prognostic information regarding adverse outcomes in HFpEF patients.

Heart rate elevations over time predict a higher CV risk in HFpEF

Oct. 24, 2017 - Vazir A, et al. - J Am Coll Cardiol HF 2017

In patients with HFpEF, a higher baseline resting HR and time-updated HR and an increase in resting HR over time since the preceding clinic visit were independently associated with an elevated risk for CV events.

Heart failure & Diabetes: Time for a more unified approach

Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017
PACE-CME symposium held at ESC 2017 - Heart failure & Diabetes: Time for a more unified approach

This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017

NT-proBNP levels predict outcomes in HF patients with or without atrial fibrillation

Oct. 19, 2017 - Kristensen SL et al. - Circ Heart Fail. 2017

a concentration of 400 pg/mL, any given concentration of NT-proBNP had a similar predictive value for adverse outcomes in HFrEF patients with and without AF.

Classifying acute heart failure patients may improve quality of care and outcomes

Oct. 10, 2017 - Chioncel O et al. - Eur J Heart Fail 2017

In the ESC-HF-LT Registry, substantial differences in outcomes were found when patients were stratified by clinical profile, SBP, or congestion/hypo-perfusion phenotypes.

Abdominal obesity may be effect modifier of benefit of MRA therapy in HF patients

Sep. 20, 2017 - Olivier A et al. - Eur J Heart Failure 2017

Eplerenone improved outcomes in HFrEF patients with and without abdominal obesity, although the benefit appeared to be more pronounced among those with abdominal obesity.

SGLT2 inhibitor reduced HF outcomes independently of HF risk in diabetic patients

Sep. 19, 2017 - Fitchett D et al. - Eur Heart J 2017

Many T2DM patients with established CVD and without HF are at high or very high risk for HF outcomes. Empagliflozin reduced adverse HF outcomes both in patients at low or high HF risk.